These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33250082)

  • 1. Effects of Netarsudil on the Corneal Endothelium: Three-Month Findings from a Phase 3 Trial.
    Mundorf T; Mah F; Sheng H; Heah T
    Ophthalmol Glaucoma; 2020; 3(6):421-425. PubMed ID: 33250082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2.
    Wisely CE; Sheng H; Heah T; Kim T
    Adv Ther; 2020 Mar; 37(3):1114-1123. PubMed ID: 31981106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study.
    Khouri AS; Serle JB; Bacharach J; Usner DW; Lewis RA; Braswell P; Kopczynski CC; Heah T;
    Am J Ophthalmol; 2019 Aug; 204():97-104. PubMed ID: 30862500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).
    Serle JB; Katz LJ; McLaurin E; Heah T; Ramirez-Davis N; Usner DW; Novack GD; Kopczynski CC;
    Am J Ophthalmol; 2018 Feb; 186():116-127. PubMed ID: 29199013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2).
    Kahook MY; Serle JB; Mah FS; Kim T; Raizman MB; Heah T; Ramirez-Davis N; Kopczynski CC; Usner DW; Novack GD;
    Am J Ophthalmol; 2019 Apr; 200():130-137. PubMed ID: 30653957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One Year of Netarsudil and Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Phase 3, Randomized MERCURY-1 Study.
    Brubaker JW; Teymoorian S; Lewis RA; Usner D; McKee HJ; Ramirez N; Kopczynski CC; Heah T
    Ophthalmol Glaucoma; 2020; 3(5):327-338. PubMed ID: 32768361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study.
    Walters TR; Ahmed IIK; Lewis RA; Usner DW; Lopez J; Kopczynski CC; Heah T;
    Ophthalmol Glaucoma; 2019; 2(5):280-289. PubMed ID: 32672669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension.
    Kopczynski CC; Heah T
    Drugs Today (Barc); 2018 Aug; 54(8):467-478. PubMed ID: 30209441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension.
    Singh IP; Fechtner RD; Myers JS; Kim T; Usner DW; McKee H; Sheng H; Lewis RA; Heah T; Kopczynski CC
    J Glaucoma; 2020 Oct; 29(10):878-884. PubMed ID: 32826769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, Double-Masked Trial of Netarsudil 0.02% Ophthalmic Solution for Prevention of Corticosteroid-Induced Ocular Hypertension.
    Price MO; Feng MT; Price FW
    Am J Ophthalmol; 2021 Feb; 222():382-387. PubMed ID: 33045216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial.
    Asrani S; Robin AL; Serle JB; Lewis RA; Usner DW; Kopczynski CC; Heah T;
    Am J Ophthalmol; 2019 Nov; 207():248-257. PubMed ID: 31229466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible Corneal Endothelial Abnormalities With Netarsudil.
    Tanna AP; Esfandiari H; Teramoto K
    J Glaucoma; 2020 Jun; 29(6):e41-e43. PubMed ID: 32224803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension.
    Araie M; Sugiyama K; Aso K; Kanemoto K; Kothapalli K; Kopczynski C; Senchyna M; Hollander DA
    Adv Ther; 2021 Apr; 38(4):1757-1775. PubMed ID: 33629227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 0.02% netarsudil ophthalmic solution on intraocular pressure of normotensive dogs.
    Yang VY; Miller PE; Keys DA; La Croix NC
    Vet Ophthalmol; 2021 Mar; 24 Suppl 1():87-95. PubMed ID: 31908139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
    Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study.
    Sit AJ; Gupta D; Kazemi A; McKee H; Challa P; Liu KC; Lopez J; Kopczynski C; Heah T
    Am J Ophthalmol; 2021 Jun; 226():262-269. PubMed ID: 33524367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Netarsudil and latanoprost ophthalmic solution for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension.
    Aref AA; Geyman LS; Zakieh AR; Alotaibi HM
    Expert Rev Clin Pharmacol; 2019 Dec; 12(12):1073-1079. PubMed ID: 31842637
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of safety and efficacy of Netarsudil 0.02% and Bimatoprost 0.01% monotherapy and combination therapy in primary open-angle glaucoma and ocular hypertension.
    Shahid S; Rizvi SWA; Khan AA; Ashraf H; Akhter A
    Indian J Ophthalmol; 2024 Mar; 72(3):427-431. PubMed ID: 38146971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting.
    Zaman F; Gieser SC; Schwartz GF; Swan C; Williams JM
    Curr Med Res Opin; 2021 Jun; 37(6):1011-1020. PubMed ID: 33733980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.
    Hughes BA; Bacharach J; Craven ER; Kaback MB; Mallick S; Landry TA; Bergamini MV
    J Glaucoma; 2005 Oct; 14(5):392-9. PubMed ID: 16148589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.